Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR.

Fang, Shencun; Zhang, Meiling; Wei, Guihong; Lu, Kai-Hua

Fang, Shencun; Zhang, Meiling; Wei, Guihong; Lu, Kai-Hua.

Afiliación

Fang S; Department of Respiratory Medicine Center, Nanjing Chest Hospital, Nanjing, Jiangsu, China.
Zhang M; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Wei G; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Lu KH; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Oncotarget ; 9(6): 7175-7181, 2018 Jan 23.

Article en En | MEDLINE | ID: mdl-29467959

Palabras clave

VEGFR-2; angiogenesis; apatinib; non-small-cell lung cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Oncotarget Año: 2018 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google